AU2015355169A1 - Animal model for dry eye and methods of use of such animals - Google Patents

Animal model for dry eye and methods of use of such animals Download PDF

Info

Publication number
AU2015355169A1
AU2015355169A1 AU2015355169A AU2015355169A AU2015355169A1 AU 2015355169 A1 AU2015355169 A1 AU 2015355169A1 AU 2015355169 A AU2015355169 A AU 2015355169A AU 2015355169 A AU2015355169 A AU 2015355169A AU 2015355169 A1 AU2015355169 A1 AU 2015355169A1
Authority
AU
Australia
Prior art keywords
candidate agent
scopolamine
administered
benzalkonium chloride
dry eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015355169A
Other languages
English (en)
Inventor
Jingtai Cao
Ying Hu
Carmelo Romano
Ming Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2015355169A1 publication Critical patent/AU2015355169A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Educational Technology (AREA)
  • Pure & Applied Mathematics (AREA)
  • Medical Informatics (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Theoretical Computer Science (AREA)
  • Algebra (AREA)
  • Business, Economics & Management (AREA)
AU2015355169A 2014-12-02 2015-12-01 Animal model for dry eye and methods of use of such animals Abandoned AU2015355169A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086263P 2014-12-02 2014-12-02
US62/086,263 2014-12-02
PCT/US2015/063084 WO2016089807A1 (en) 2014-12-02 2015-12-01 Animal model for dry eye and methods of use of such animals

Publications (1)

Publication Number Publication Date
AU2015355169A1 true AU2015355169A1 (en) 2017-05-25

Family

ID=55024246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015355169A Abandoned AU2015355169A1 (en) 2014-12-02 2015-12-01 Animal model for dry eye and methods of use of such animals

Country Status (14)

Country Link
US (1) US20170360013A1 (enExample)
EP (1) EP3226853B1 (enExample)
JP (1) JP6692808B2 (enExample)
KR (1) KR20170100483A (enExample)
CN (1) CN107106553A (enExample)
AU (1) AU2015355169A1 (enExample)
CA (1) CA2967432A1 (enExample)
ES (1) ES2759729T3 (enExample)
IL (1) IL252077A0 (enExample)
MX (1) MX2017007295A (enExample)
RU (1) RU2706787C2 (enExample)
SG (1) SG11201703572SA (enExample)
WO (1) WO2016089807A1 (enExample)
ZA (1) ZA201703052B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909998T3 (es) * 2016-10-14 2022-05-11 I Com Medical Gmbh Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
US12303527B2 (en) 2018-04-18 2025-05-20 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
CN113519461A (zh) * 2021-07-06 2021-10-22 江西中洪博元生物技术有限公司 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用
WO2023215261A1 (en) * 2022-05-02 2023-11-09 Ocular Services On Demand, Llc Mammalian eye models

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384679A1 (en) * 1999-09-08 2001-03-15 Srinivasan Venkateshwaran Using quaternary ammonium salts for transdermal drug delivery
EP2598131A1 (fr) * 2010-07-29 2013-06-05 Laboratoires Fournier S.A. Composes pour le traitement/la prevention des maladies inflammatoires oculaires

Also Published As

Publication number Publication date
RU2017118978A (ru) 2019-01-09
ES2759729T3 (es) 2020-05-12
RU2706787C2 (ru) 2019-11-21
EP3226853A1 (en) 2017-10-11
CN107106553A (zh) 2017-08-29
KR20170100483A (ko) 2017-09-04
SG11201703572SA (en) 2017-05-30
CA2967432A1 (en) 2016-06-09
US20170360013A1 (en) 2017-12-21
IL252077A0 (en) 2017-07-31
RU2017118978A3 (enExample) 2019-06-04
MX2017007295A (es) 2018-03-12
JP6692808B2 (ja) 2020-05-13
EP3226853B1 (en) 2019-09-04
WO2016089807A1 (en) 2016-06-09
ZA201703052B (en) 2019-03-27
JP2018500546A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
EP3226853B1 (en) Animal model for dry eye and methods of use of such animals
Xie et al. Erythropoietin protects the inner blood–retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy
De Paiva et al. Dry eye–induced conjunctival epithelial squamous metaplasia is modulated by interferon-γ
Cao et al. Deletion of aquaporin-4 aggravates brain pathology after blocking of the meningeal lymphatic drainage
Baudouin et al. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis)
Luo et al. Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1
Brodeur et al. IL-21 promotes pulmonary fibrosis through the induction of profibrotic CD8+ T cells
Sumpter et al. Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses
Tolentino et al. Investigational drugs in clinical trials for macular degeneration
Lee et al. Corneal lymphangiogenesis in dry eye disease is regulated by substance P/neurokinin-1 receptor system through controlling expression of vascular endothelial growth factor receptor 3
Royce et al. Intranasal administration of mesenchymoangioblast‐derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease
Cai et al. Endogenous regulatory T cells promote M2 macrophage phenotype in diabetic stroke as visualized by optical imaging
US20200054745A1 (en) Methods for treatment of age-related macular degeneration
Vitar et al. Topical neurokinin-1 receptor antagonist Fosaprepitant ameliorates ocular graft-versus-host disease in a preclinical mouse model
Jin et al. Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye
Fang et al. Piezo2 downregulation via the Cre-lox system affects aqueous humor dynamics in mice
US9555028B2 (en) Drug for preventing/treating ocular disease
Gala et al. Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α
Wang et al. Th22 cells induce Müller cell activation via the Act1/TRAF6 pathway in diabetic retinopathy
Lin et al. Comparison of treatment effect and tolerance of the topical application of mizoribine and cyclosporine A in a mouse Dry eye model
JP5800263B2 (ja) アレルギー性鼻炎治療剤のスクリーニング方法およびその利用
US20090131359A1 (en) Antifibrotic therapy
KR101794225B1 (ko) 안지오제닌을 유효성분으로 함유하는 각막 내피의 창상 치료용 약학조성물
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
Huo et al. Influence of plasma exchange on transplantation related immune function in patients with liver failure.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted